Adding liraglutide to standard diabetes treatment improved kidney function (lower creatinine, BUN, and urinary protein), reduced renal fibrosis, and boosted immune markers in 42 T2DM patients compared to standard therapy alone.
97.6% vs 78.6%Treatment effectiveness rate for liraglutide + standard therapy vs standard therapy alone in T2DM patients
What the researchers found
Liraglutide + standard therapy achieved 97.6% effectiveness vs 78.6% for standard therapy alone, with significantly better blood glucose control, kidney function (Scr, BUN, 24h-UPor), renal fibrosis reduction, and immunoglobulin levels in 84 T2DM patients.
Why it matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. Evidence that liraglutide not only controls blood sugar but also directly improves kidney function and reduces fibrosis supports its use as a kidney-protective therapy for diabetic patients.
The numbers in context
84 patients total (42 per group). Study period: March 2021 to March 2022. Improvements in renal function, fibrosis markers, and immune parameters.
How the study worked
Retrospective analysis of 84 T2DM patients (42 per group) at First Affiliated Hospital of Jishou University (March 2021–March 2022). Control group received routine treatment; study group added liraglutide. Compared blood glucose, renal function, renal fibrosis markers, immunoglobulin levels, and adverse reactions.
Who was studied
Type 2 diabetes patients at a Chinese university hospital
What this study cannot tell us
Retrospective, non-randomized design at a single hospital with a small sample size (42 per group). The higher adverse reaction rate in the liraglutide group (19.1%) is notable and warrants attention. Short follow-up period. The study didn't control for all potential confounders.
How to read the evidence
Moderate evidence from a small retrospective cohort study (84 patients). Results are suggestive but limited by the non-randomized design, single center, and small sample size.
When this study was published
Published in 2024 covering patients treated March 2021–March 2022.
The bigger picture
GLP-1 receptor agonists are increasingly recognized for kidney protection beyond blood sugar control. This adds to growing evidence that liraglutide may directly reduce kidney damage through anti-inflammatory and anti-fibrotic mechanisms, which could change how clinicians prioritize diabetes medications for patients at risk of kidney disease.
Questions still open
- What specific adverse reactions occurred in the liraglutide group, and were any serious?
- Do the kidney benefits persist long-term, or are they only seen during active treatment?
- Would these kidney-protective effects be seen in patients with more advanced diabetic nephropathy?
Common questions
Can liraglutide protect kidneys in diabetic patients?
Why did the liraglutide group have more side effects?
Read the original research
Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.
American journal of translational research, 16(7), 3405-3412
Citation
Xiong, Wen; Liu, Hongxia; Xiang, Bo; Shang, Guangyu. (2024). Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.. American journal of translational research, 16(7), 3405-3412. https://doi.org/10.62347/VYSW5854